Elevated serum growth differentiation factor 15 in multiple system atrophy patients:A case control study  

作　　者：Tao Yue Hui Lu Xiao-Mei Yao Xia Du Ling-Ling Wang Dan-Dan Guo Yi-Ming Liu 

机构地区：[1]Department of Neurology,Qilu Hospital,Cheeloo College of Medicine,Shandong University,Jinan 250012,Shandong Province,China [2]Department of Gerontology,Zibo Central Hospital,Zibo 255036,Shandong Province,China [3]Department of Ophthalmology,Zibo Central Hospital,Zibo 255036,Shandong Province,China [4]Department of Gerontology,Jinan Central Hospital,Cheeloo College of Medicine,Shandong University,Jinan 250013,Shandong Province,China [5]Department of Neurology,Jinan Central Hospital Affiliated to Shandong University,Jinan 250013,Shandong Province,China [6]Department of Neurology,Yantaishan Hospital,Yantai 264001,Shandong Province,China

出　　处：《World Journal of Clinical Cases》2020年第12期2473-2483,共11页世界临床病例杂志

基　　金：Supported by National Natural Science Foundation of China,No.81771373;Key Research and Development Plan of Zibo City,No.2019ZC010169 and No.2019ZC010166.

摘　　要：BACKGROUND Multiple system atrophy(MSA) is a serious progressive neurodegenerative disease. Early diagnosis of MSA is very difficult, and diagnostic biomarkers are limited. Growth differentiation factor 15(GDF15) is involved in the differentiation and progression of the central nervous system, and is widely distributed in peripheral blood, which may be a novel biomarker for MSA.AIM To determine serum GDF15 levels, related factors and their potential diagnostic value in MSA patients, compared with Parkinson’s disease(PD) patients and healthy controls.METHODS A case-control study was conducted, including 49 MSA patients, 50 PD patients and 50 healthy controls. Serum GDF15 levels were measured by human enzymelinked immunosorbent assay, and the differences between the MSA, PD and control groups were analyzed. Further investigations were performed in different MSA subgroups according to age of onset, sex, clinical subtypes, diagnostic criteria, and disease duration. Receiver-operating characteristic curve analysiswas used to evaluate the diagnostic value of GDF15, especially for the differential diagnosis between MSA and PD.RESULTS Serum GDF15 levels were significantly higher in MSA patients than in PD patients and healthy controls(P = 0.000). Males and those with a disease duration of more than three years showed higher serum GDF15 levels(P = 0.043 and 0.000;respectively). Serum GDF15 levels may be a potential diagnostic biomarker for MSA patients compared with healthy controls and PD patients(cutoff: 470.42 pg/m L, sensitivity: 85.7%, specificity: 88.0%;cutoff: 1075.91 pg/m L, sensitivity:51.0%, specificity: 96.0%;respectively).CONCLUSION Serum GDF15 levels are significantly higher in MSA patients and provide suggestions on the etiology of MSA.

关 键 词：Multiple system atrophy Parkinson’s disease Serum growth differentiation factor 15 BIOMARKER Receiver-operating characteristic curve Neurodegenerative disease 

分 类 号：R741[医药卫生—神经病学与精神病学]